Ambenonium is a cholinesterase inhibitor that targets both muscarinic and nicotinic receptors indicated for the treatment of myasthenia gravis. A medication used to treat myasthenia gravis (a disease that causes weakness in important muscles responsible for things like movement and breathing).
- Mechanism
- Curator reviewed
Ambenonium exerts its actions against myasthenia gravis by competitive, reversible inhibition of acetylcholinesterase. The disease myasthenia gravis occurs when the body inappropriately produces antibodies against acetylcholine receptors, and thus inhibits proper acetylcholine signal transmission (when acetylcholine binds to acetylcholine receptors of striated muscle fibers, it stimulates those fibers to contract). Ambenonium reversibly binds acetylcholinesterase at the anionic site, which results in the blockage of the site of acetycholine binding, thereby inhibiting acetylcholine hydrolysis and enhancing cholinergic function through the accumulation of acetycholine at cholinergic synpases. Elevated acetylcholine levels lead to facilitates transmission of impulses across the myoneural junction.
- Primary indication
- Ambenonium is used to treat muscle weakness due to muscle disease (myasthenia gravis).Curator reviewed
- Formula / weight
- C28H42Cl2N4O2 · 537.565 g/mol (avg)
- First approval
- United States, 1971
- Also known as
- Ambenonum
Resolves to
OMHBPUNFVFNHJK-UHFFFAOYSA-PSMILESCC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC1=CC=CC=C1ClWhat you can answer from here — as of September 12, 2026
Which drugs share a target with Ambenonium, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account